[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)

R Seifert, L Emmett, SP Rowe, K Herrmann… - European Urology, 2023 - Elsevier
Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …

Prostate-specific membrane antigen ligands for imaging and therapy

M Eiber, WP Fendler, SP Rowe, J Calais… - Journal of Nuclear …, 2017 - Soc Nuclear Med
The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate
cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over …

German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients

K Rahbar, H Ahmadzadehfar… - Journal of Nuclear …, 2017 - Soc Nuclear Med
177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients

FL Giesel, B Hadaschik, J Cardinale, J Radtke… - European journal of …, 2017 - Springer
Purpose The prostate-specific membrane antigen (PSMA) targeted positron-emitting-
tomography (PET) tracer 68 Ga-PSMA-11 shows great promise in the detection of prostate …

Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a …

J Kuten, I Fahoum, Z Savin, O Shamni… - Journal of Nuclear …, 2020 - Soc Nuclear Med
18F-PSMA-1007 is a novel prostate-specific membrane antigen (PSMA)–based
radiopharmaceutical for imaging prostate cancer (PCa). The aim of this study was to …

PSMA ligands for PET imaging of prostate cancer

SM Schwarzenboeck, I Rauscher… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-
labeled PET agents has become increasingly important in recent years. Imaging of …

Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis

K Rahbar, M Schmidt, A Heinzel, E Eppard… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Radiolabeled prostate-specific membrane antigen (PSMA) ligands represent a true
theranostic concept for diagnosis and therapy in patients with relapsed or metastatic …

68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review

J Corfield, M Perera, D Bolton, N Lawrentschuk - World journal of urology, 2018 - Springer
Purpose To systematically review currently available data on 68 Ga-prostate specific
membrane antigen (PSMA) positron emission tomography (PET) used for the primary …

Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer

RM Hicks, JP Simko, AC Westphalen, HG Nguyen… - Radiology, 2018 - pubs.rsna.org
Purpose To compare the diagnostic accuracy of gallium 68 (68Ga)–labeled prostate-specific
membrane antigen (PSMA)–11 PET/MRI with that of multiparametric MRI in the detection of …

Immunohistochemical validation of PSMA expression measured by 68Ga-PSMA PET/CT in primary prostate cancer

N Woythal, R Arsenic, C Kempkensteffen… - Journal of Nuclear …, 2018 - Soc Nuclear Med
68Ga-labeled prostate-specific membrane antigen (68Ga-PSMA) PET/CT has a proven role
in staging and restaging of prostate cancer (PCA). The aims of this study were to evaluate …